Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Comparative Effectiveness Research Resource Center

Featured

News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023

Marta Rybczynski

Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023

Yvette C Terrie

Yvette C Terrie
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Cancer Care Equity and Collaboration
10/16/2022

Katie Herman and Craig Ostroff

Katie Herman and Craig Ostroff ...
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical Pathways Congress, Lawrence N Shulman, MD, Abramson Cancer Center University of Pennsylvania, summarized the status of cancer care in the United States and proposed how collaborative care can enhance quality of...
At the 2022 Oncology Clinical...
10/16/2022
Journal of Clinical Pathways
News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
Carboplatin Monotherapy vs Carboplatin Plus Paclitaxel for Older Women With Ovarian Cancer
05/12/2021
05/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Acalabrutinib for Patients With CLL
04/19/2021
04/19/2021
Journal of Clinical Pathways
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
02/24/2021
02/24/2021
Journal of Clinical Pathways
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
02/23/2021
02/23/2021
Journal of Clinical Pathways
News
Sequential or Concurrent Chemoradiation vs Radiation Alone After Hysterectomy for Cervical Cancer
01/28/2021
01/28/2021
Journal of Clinical Pathways

News

News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023

Marta Rybczynski

Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023

Yvette C Terrie

Yvette C Terrie
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
Carboplatin Monotherapy vs Carboplatin Plus Paclitaxel for Older Women With Ovarian Cancer
05/12/2021
05/12/2021
Journal of Clinical Pathways
News
Sequential or Concurrent Chemoradiation vs Radiation Alone After Hysterectomy for Cervical Cancer
01/28/2021
01/28/2021
Journal of Clinical Pathways
News
Comparative Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
01/27/2021
01/27/2021
Journal of Clinical Pathways
News
Targeted Gene Testing-Directed Treatment Cost-Effective for Metastatic GIST
10/06/2020
10/06/2020
Journal of Clinical Pathways
News
No Significant PFS Improvement With KRd Vs VRd in Newly Diagnosed MM
10/01/2020
10/01/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Larotrectinib Vs Entrectinib for Metastatic NSCLC
09/09/2020
09/09/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice
09/03/2020
09/03/2020
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Videos

Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
02/24/2021
02/24/2021
Journal of Clinical Pathways
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
02/23/2021
02/23/2021
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 2)
05/20/2024
Michael Kolodziej, MD
John Hennessy, MBA
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part...
05/20/2024
Cancer Care Business Exchange
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement